EANM-EORTC general recommendations for sentinel node diagnostics in melanoma
Annette H. Chakera(Rigshospitalet), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Alan Spatz(Jewish General Hospital), Corrado Caracò(Istituto di Chimica Biomolecolare), James R. Ballinger(Guy's and St Thomas' NHS Foundation Trust), A. J. Britten(St George's Hospital), Martín C. Mihm(Harvard University), Hans Starz(University Hospital Augsburg), Richard Essner(Saint John's Health Center), John F. Thompson(Melanoma Institute Australia), Alexander M.M. Eggermont(University Medical Center Utrecht), Einat Even‐Sapir(Tel Aviv Sourasky Medical Center), Zeynep Burak(Ege University), Tanja Gmeiner Stopar(Ljubljana University Medical Centre), Omgo E. Nieweg, Giuseppe Trifirò(European Institute of Oncology), Richard A. Scolyer(The University of Sydney), Giuseppe Viale(University of Milan), Arturo Chiti(Vita-Salute San Raffaele University), Christian Ingvar(Lund University), Krzysztof T. Drzewiecki(Rigshospitalet), Martin Cook(Royal Surrey NHS Foundation Trust), Roger F. Uren(The University of Sydney), Alistair J. Cochran(Western Infirmary), Stanley W. McCarthy(Royal Prince Alfred Hospital), Wendy A. Waddington(University College London Hospitals NHS Foundation Trust), Sergi Vidal‐Sicart(Hospital Clínic de Barcelona), Nicola Mozzillo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Birger Hesse(Copenhagen University Hospital)
Cited by 167
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k